SEC Form 4 · accession 0001562180-15-000659
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO, Secretary and Treasurer
Period of report
Aug 10, 2015
Accepted (ET)
Aug 11, 2015 · 11:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 10, 2015 | S | 2,762 | $67.95 | D | 88,801 | D | |
| Common StockF3 | Aug 10, 2015 | S | 900 | $67.20 | D | 87,901 | D | |
| Common StockF4 | Aug 10, 2015 | S | 338 | $65.88 | D | 87,563 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $67.35 USD to $68.32 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $66.75 USD to $67.31 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $65.53 USD to $66.10 USD. The price reported above reflects the weighted average sale price.